Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.

Pérez-López ME, Curiel T, Gómez JG, Jorge M

Department of Clinical Oncology, Orense Hospital Complex, and Department of Clinical Oncology, Santiago de Compostela University Hospital Complex, Spain.

The most significant factor predicting response to second-line chemotherapy is the time interval elapsed from the end of chemotherapy to relapse occurrence. Two types of situations may be considered: patients with platinum-sensitive relapse (relapse-free interval longer than 6 months) and patients with platinum-refractory relapse (progression during treatment or relapse-free interval under 6 months). Pegylated liposomal doxorubicin is a doxorubicin formulation. Encapsulation in liposomes confers it different pharmacokinetic characteristics and a more favorable toxicity profile. The following review examines the efficacy and safety of pegylated liposomal doxorubicin for the treatment of relapsing epithelial ovarian cancer.

Published 6 April 2007 in Anticancer Drugs, 18(5): 611-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.